India slashes taxes on three anticancer drugs to make them more affordable for patients.

The Indian government has reduced the Maximum Retail Price (MRP) of three anticancer drugs—Trastuzumab Deruxtecan, Osimertinib, and Durvalumab—by cutting customs duties to zero and reducing GST rates from 12% to 5%. This move aims to lower costs for cancer patients and improve access to these medications. Manufacturers have complied with the directive and updated their prices accordingly.

4 months ago
3 Articles